Panoramica

Idoneità

Dettagli del Disegno

Bracci e Interventi

Misure di Esito

Siti dello Studio

Fonte: NCT06672185

Reclutamento in corso

ARC101 in Advanced Solid Tumors

Interventistico

Fase 1

Sponsor: Third Arc Bio

Ultimo Aggiornamento: 3 aprile 2026
Avviso - Le informazioni provengono da registri pubblici e potrebbero non riflettere i cambiamenti in tempo reale presso il centro locale.

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.

Categoria di Trattamento

Altri Farmaci

Mutazioni richieste

Nessuno

Studio Iniziato

5 febbraio 2025

Ultimo Aggiornamento dello Sponsor

3 aprile 2026

Completamento Stimato

1 maggio 2028

Contatto dello studio

Nome:VP Clinical Operations

Email:clinicaltrials@thirdarcbio.com

Telefono:267-589-9444

Idoneità

Criteri di Inclusione

* Locally advanced or metastatic solid tumor ovarian, testicular or other Claudin 6+ cancers

* Measurable or evaluable disease, per RECIST v1.1

* Eastern Cooperative Oncology Group (ECOG) performance status 0-1

* Adequate organ function

Criteri di Esclusione

* Active CNS involvement

* Malignancy diagnosis other than the disease under study within 2 years prior to the first dose of study drug.

* Presence of uncontrolled ascites

* Toxicity related to prior anticancer therapy that has not returned to Grade ≤1 or baseline levels

* Clinically significant pulmonary compromise

* Active autoimmune disease within 12 months prior to first dose of study drug.

* Female participant who is pregnant, breastfeeding, or plans to become pregnant or male participant who plans to father a child either while enrolled or within 90 days after the final administration of study drug.

Pensi che questo studio appaia erroneamente?

Dettagli del Disegno

AllocazioneNon-Randomized

Modello di InterventoSequential Assignment

MascheramentoNone (Open Label)

Numero da Arruolare70

Bracci e Interventi

Bracci

Interventi

Tipo: Experimental

Descrizione: ARC101 will be administered in escalating doses, with each dose escalation cohort assessing toxicity 21 days after the initial dose.

Interventi:

ARC101

Misure di Esito

Misure di Esito Primarie

Frequency and type of dose-limiting toxicities.Day 1-Day 21 of the first treatment cycle

Occurrence and severity of adverse events, serious adverse events and laboratory values.Day 1 to 100 days after the last dose of study drug.

Misure di Esito Secondarie

PK Assessment: Cmax of ARC101During the intervention/study therapy administration, approximately 1 year on average.

Measurement of Maximum Observed Concentration

PK Assessment: Cmin of ARC101During the intervention/study therapy administration, approximately 1 year on average.

Measurement of Minimum Observed Concentration

PK Assessment: Tmax of ARC101During the intervention/study therapy administration, approximately 1 year on average.

Measurement of Time to Reach Maximum Concentration

PK Assessment: AUC of ARC101During the intervention/study therapy administration, approximately 1 year on average.

Area under the plasma concentration versus time curve

Overall Response RateDuring the intervention/study therapy administration, approximately 1 year on average.

Percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1 and overall survival (OS)

Duration of ResponseDuring the intervention/study therapy administration, approximately 1 year on average.

Time from first objective response to disease progression per RECIST 1.1 or death to any cause

Progression-Free SurvivalDuring the intervention/study therapy administration, approximately 1 year on average.

PFS is defined as the time from the start of the treatment until objective disease progression per PFS is defined as the time from the start of the treatment until objective disease progression per RECIST 1.1 or death from any cause

Number of anti-drug antibody (ADA) Positive ParticipantsDuring the intervention/study therapy administration, approximately 1 year on average.

Immunogenicity will be measured by the number of participants that are ADA positive.

Aggiungi studio ai preferiti

Condividi Studio

Scarica lo studio

Pensi che questo studio appaia erroneamente?

Segnala Studio

Scarica lo studio

Siti dello Studio

Nessun dato

No matching sites found.

Loading Maps...